| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/03/2002 | WO2002000913A2 MODULATION OF β-AMYLOID LEVELS BY β-SECRETASE BACE2 |
| 01/03/2002 | WO2002000887A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | WO2002000878A2 Human msp1 mitochondrial dynamin, its msp1-x isoforms, and their therapeutic use |
| 01/03/2002 | WO2002000872A2 Compositions and methods for treating or detecting degenerative diseases of the motor neurons |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000849A1 Cell fraction containing cells capable of differentiating into nervous system cells |
| 01/03/2002 | WO2002000727A2 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | WO2002000725A2 G-protein coupled receptor org10 |
| 01/03/2002 | WO2002000713A1 Prion-binding activity in serum and plasma determined as plasminogen and fibrinogen |
| 01/03/2002 | WO2002000710A2 B7-like molecules and uses thereof |
| 01/03/2002 | WO2002000691A2 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | WO2002000684A2 Method of obtaining peptides with tissue-specific activity and pharmaceutical compositions on their basis |
| 01/03/2002 | WO2002000676A1 Purine derivatives |
| 01/03/2002 | WO2002000662A1 Improvements in and relating to chromophores |
| 01/03/2002 | WO2002000661A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| 01/03/2002 | WO2002000659A2 Methods of synthesis for 9-substituted hypoxanthine derivatives |
| 01/03/2002 | WO2002000645A1 Indole derivatives useful for the treatment of cns disorders |
| 01/03/2002 | WO2002000638A2 Substituted phthalides as anti-convulsive drugs |
| 01/03/2002 | WO2002000631A2 Benzhydryl derivatives |
| 01/03/2002 | WO2002000629A1 Iminopyrimidine nmda nr2b receptor antagonists |
| 01/03/2002 | WO2002000626A1 Fused azepine derivatives and their use as antidiuretic agents |
| 01/03/2002 | WO2002000623A2 Aryl fused substituted 4-oxy-pyridines |
| 01/03/2002 | WO2002000621A1 Compounds exhibiting x-type spla2 inhibiting effect |
| 01/03/2002 | WO2002000603A1 Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates |
| 01/03/2002 | WO2002000602A1 Benzophenones and sulfones as inhibitors of glycine uptake |
| 01/03/2002 | WO2002000260A1 Remedial agent for optic nerve disease and the like |
| 01/03/2002 | WO2002000257A1 Remedies for alzheimer's disease |
| 01/03/2002 | WO2002000245A1 Neurotoxic oligomers |
| 01/03/2002 | WO2002000237A1 Therapeutical use of sophora flavescens or sophora subprostrata extracts |
| 01/03/2002 | WO2002000236A1 Extracts from sophora species, method for producing the same and their use |
| 01/03/2002 | WO2002000225A1 7-hydroxyepiandrosterone having neuroprotective activity |
| 01/03/2002 | WO2002000224A1 Neuroprotective 7-beta-hydroxysteroids |
| 01/03/2002 | WO2002000217A1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 01/03/2002 | WO2002000213A1 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| 01/03/2002 | WO2002000210A2 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease |
| 01/03/2002 | WO2002000209A2 Gabapentin analogues for sleep disorders |
| 01/03/2002 | WO2002000203A1 Topical pharmaceutical formulations and methods of treatment |
| 01/03/2002 | WO2002000195A2 Methods and compositions for treating pain of the mucous membrane |
| 01/03/2002 | WO2002000172A2 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | WO2002000167A2 Modified forms of pharmacologically active agents and uses therefor |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001072741A3 N-benzodioxanylmethyl-1-piperidyl-methylamine compounds for the treatment of central nervous system disorders |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001070693A3 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
| 01/03/2002 | WO2001066564A3 Gamma-secretase inhibitors |
| 01/03/2002 | WO2001066544A3 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 01/03/2002 | WO2001062233A3 Adenosine receptor modulators |
| 01/03/2002 | WO2001058472A3 Botulinum toxin pharmaceutical compositions |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/03/2002 | WO2001053461A9 Multipotent neural stem cells from peripheral tissues and uses thereof |
| 01/03/2002 | WO2001051473A8 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| 01/03/2002 | WO2001049270A3 Odor-masking coating for a pharmaceutical preparation |
| 01/03/2002 | WO2001045689A3 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 01/03/2002 | WO2001042265A3 N6 heterocyclic 8-modified adenosine derivatives |
| 01/03/2002 | WO2001032877A3 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 01/03/2002 | WO2000061171A9 Uses of mammalian ox2 protein and related reagents |
| 01/03/2002 | WO2000058282A3 Novel [(2-substituted-5 -[3-thienyl) -benzyl]-[2- ([2-isopropoxy-5-fluoro] -phenoxy) -ethyl] -amine derivatives, method for the production and use thereof as medicaments |
| 01/03/2002 | US20020002282 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
| 01/03/2002 | US20020002269 Artemin, a neurotrophic factor |
| 01/03/2002 | US20020002203 Administering an effective amount of a compound selected from aryl(and heterocyclic) ureido and aryl(heterocyclic) carboxamido phenoxyisobutyric acids as inhibitor of glycation and advanced glycation endproducts (AGEs) (protein-aging) |
| 01/03/2002 | US20020002191 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 01/03/2002 | US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides |
| 01/03/2002 | US20020002176 Apomorphine and norapomorphine N-glucuronides, O-sulfates, O-glucuronides, N-sulfates, O-phosphates and N-phosphates, esters, ethers, and N-alkyls; sexual disorders and Parkinson's disease; bioavailability; side effect reduction |
| 01/03/2002 | US20020002174 Serotonin antagonists |
| 01/03/2002 | US20020002170 Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation |
| 01/03/2002 | US20020002168 Heterocyclic carboxamides |
| 01/03/2002 | US20020002167 Calcium channel antagonists used to treat ischemic cerebrovascular disorders |
| 01/03/2002 | US20020002165 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 01/03/2002 | US20020002163 1,4-benzodiazepinones and their uses as CCK antagonists |
| 01/03/2002 | US20020002161 5-HT ligands used to treat central nervous system disorders |
| 01/03/2002 | US20020002149 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| 01/03/2002 | US20020002144 Contacting acetyl coenzyme A with an alkylating derivative of an acetyl acceptor substrate in the presence of an acetyltransferase; antidepressants, analgesics, antipsychotics |
| 01/03/2002 | US20020002141 For inhibiting apoptosis or apoptosis-like cell death |
| 01/03/2002 | US20020002137 Combination of growth hormone secretagogues and antidepressants |
| 01/03/2002 | US20020001840 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 01/03/2002 | US20020001598 Pharmaceutical microspheres containing valproic acid for oral administration |
| 01/03/2002 | US20020001592 Use of Botulinum toxins for treating various disorders and conditions and associated pain |
| 01/03/2002 | DE10030375A1 Verwendung von MTP-Inhibitoren zur Senkung von ppTRL Use of MTP inhibitors to reduce ppTRL |
| 01/03/2002 | DE10029371A1 Heterocyclische Aminoalkylpyridinderivate als Psychopharmaka Heterocyclic Aminoalkylpyridinderivate as psychotropic drugs |
| 01/03/2002 | DE10028204A1 Verfahren zur Auffindung von medizinisch wertvollen Wirkstoffen Method for identifying medically valuable active ingredients |
| 01/03/2002 | CA2414210A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | CA2414150A1 Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof |
| 01/03/2002 | CA2414115A1 Indole derivatives useful for the treatment of cns disorders |
| 01/03/2002 | CA2414089A1 Improvements in and relating to chromophores |
| 01/03/2002 | CA2413910A1 Cell fractions containing cells capable of differentating into neural cells |
| 01/03/2002 | CA2413752A1 Substituted phthalides as anti-convulsive drugs |
| 01/03/2002 | CA2413742A1 Prion-binding activity in serum and proteins |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413547A1 B7-like molecules and uses thereof |
| 01/03/2002 | CA2413545A1 Methods and compositions for treating pain of the mucous membrane |
| 01/03/2002 | CA2413354A1 Neurotoxic a.beta. oligomers in alzheimer's disease |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2413209A1 Modulation of a.beta. levels by .beta.-secretase bace2 |
| 01/03/2002 | CA2413201A1 Treatment for cardiovascular disease |
| 01/03/2002 | CA2412640A1 Iminopyrimidine nmda nr2b receptor antagonists |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/03/2002 | CA2412610A1 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | CA2412568A1 Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates |
| 01/03/2002 | CA2412555A1 Fused azepine derivatives and their use as antidiuretic agents |
| 01/03/2002 | CA2412490A1 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |